Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.
Clinical Trial Corner
Advertisement
A patient with glioblastoma, a type of brain cancer, was dosed with a novel combination immunotherapy as part of a phase 2b trial.
Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.
The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”
This summer, a trial will kick off studying ISM3091 in patients with advanced solid tumors.
Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.
The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.
A clinical trial studying an accelerated dose of Besremi recently kicked off.
A clinical trial is underway for STX-478, a potential new treatment for breast cancer and other tumors, with initial results expected later this year.
OKN-007 is being evaluated both alone and in combination with chemotherapy for patients with glioma or glioblastoma — both types of brain cancer.
Advertisement
The phase 3 Pragmatica-Lung study evaluating Cyramza and Keytruda has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.
Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.
A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.
The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer.
Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.
The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.
The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.
Researchers are recruiting patients with ER-positive, HER2-negative breast cancer to participate in a trial evaluating (Z)-endoxifen.
A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.
A clinical trial just kicked off, analyzing Padcev in patients with advanced, unresectable bladder cancer.
Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.
After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.
The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.
A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.
The treatment previously demonstrated significantly improved overall survival for patients with recurrent glioblastoma in a phase 1 study.
VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.
Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.
A phase 2 study will investigate the efficacy of darovasertib for patients with uveal melanoma and whether the drug can potentially result in lower radiation doses or fewer eye removal surgeries.
The multicenter study is evaluating the safety and efficacy of nanrilkefusp alfa combined with Erbitux.
Advertisement
Advertisement
